Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Uveitis Associated with Monogenic Autoinflammatory Syndromes in Children.

Ocular immunology and inflammation·2023
Same author

Infliximab in chronic non-infectious paediatric uveitis refractory to previous biologic therapy.

Eye (London, England)·2023
Same author

Management of paediatric ocular inflammatory disease in the UK: national survey of practice.

Eye (London, England)·2019
Same author

Application of OCT-angiography to characterise the evolution of chorioretinal lesions in acute posterior multifocal placoid pigment epitheliopathy.

Eye (London, England)·2017
Same author

Doyne lecture 2016: intraocular health and the many faces of inflammation.

Eye (London, England)·2016
Same author

The role of lipoprotein-associated phospholipase A2 in a murine model of experimental autoimmune uveoretinitis.

PloS one·2015
Same journal

Vaginal mucosa as an alternative eye-covering tissue in modified osteo-odonto-keratoprosthesis.

Eye (London, England)·2026
Same journal

Prevalence of and risk factors for diabetic retinopathy: The Thessaloniki Eye Study.

Eye (London, England)·2026
Same journal

Eyelid margin tick masquerading as a naevus in a child.

Eye (London, England)·2026
Same journal

Full-thickness macular penetration by welding laser injury.

Eye (London, England)·2026
Same journal

Incidence and characteristics of newly formed polypoidal lesions in polypoidal choroidal vasculopathy.

Eye (London, England)·2026
Same journal

Traumatic intravitreal egg-shaped hematoma.

Eye (London, England)·2026
See all related articles

Related Experiment Video

Updated: Jun 21, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Switching biologic agents for uveitis.

N Dhingra1, J Morgan, A D Dick

  • 1Academic Unit of Ophthalmology, Bristol Eye Hospital, Bristol, UK. ndhingra@doctors.org.uk

Eye (London, England)
|August 4, 2009
PubMed
Summary
This summary is machine-generated.

Switching biological agents can help patients with refractory uveitis regain control of eye inflammation and systemic symptoms. This strategy may restore remission when initial treatments lose effectiveness, improving patient management.

More Related Videos

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Related Experiment Videos

Last Updated: Jun 21, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Area of Science:

  • Ophthalmology
  • Rheumatology
  • Immunology

Background:

  • Refractory uveitis poses a significant challenge in managing sight-threatening ocular inflammation.
  • Loss of response to initial biological agents necessitates exploring alternative treatment strategies.

Observation:

  • This case series reviewed seven patients with refractory uveitis who switched between biological agents (infliximab, adalimumab).
  • Reasons for switching included controlling systemic symptoms, uveitis flares, or improving drug administration ease.
  • Patients included adults with sarcoidosis, ankylosing spondylitis, sero-negative polyarthropathy, and children with juvenile idiopathic arthritis.

Findings:

  • Switching biological agents successfully restored control of intraocular inflammation in patients with refractory uveitis.
  • Systemic symptoms were also managed effectively post-switch.
  • Concomitant immunosuppression was reduced or maintained, with a decrease in corticosteroid use.

Implications:

  • Switching biological agents is a viable strategy for managing refractory uveitis when initial therapies fail.
  • This approach can help maintain or regain remission, control systemic disease, and simplify treatment administration.
  • Further research is warranted to confirm these findings in larger cohorts.